Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Update on Antiplatelet Therapy for Stroke Prevention

Update on Antiplatelet Therapy for Stroke Prevention REVIEW ARTICLE Update on Antiplatelet Therapy for Stroke Prevention Ralph L. Sacco, MD; Mitchell S. Elkind, MD he high rates of mortality and long-term disability associated with ischemic stroke, coupled with its prevalence, necessitate good, long-term preventive strategies. Risk-factor man- agement is effective for individuals with preclinical and clinical cerebrovascular dis- T ease. Patients suffering from a transient ischemic attack or stroke are particularly vul- nerable to subsequent stroke. Most of these individuals are candidates for antiplatelet treatment to prevent a recurrence. Available antiplatelet therapies include aspirin, ticlopidine, and clopidogrel. The combination of low-dose aspirin plus extended-release dipyridamole has been shown to offer safe, effective antiplatelet therapy for appropriate patients. In the second European Stroke Preven- tion Study, the combination was found to be significantly more effective than either drug alone, at the cost of relatively few treatment-related adverse effects. This combination is currently rec- ommended as one of the first-line treatments for stroke prevention after first transient ischemic attack or stroke. Stroke has a tremendous impact on pub- stroke. Until recently, the appropriate dose lic health. It is the third leading cause of of aspirin and the value of added dipyri- death and the leading cause of substan- http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Internal Medicine American Medical Association

Update on Antiplatelet Therapy for Stroke Prevention

JAMA Internal Medicine , Volume 160 (11) – Jun 12, 2000

Loading next page...
 
/lp/american-medical-association/update-on-antiplatelet-therapy-for-stroke-prevention-wtygt0yShX
Publisher
American Medical Association
Copyright
Copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
2168-6106
eISSN
2168-6114
DOI
10.1001/archinte.160.11.1579
Publisher site
See Article on Publisher Site

Abstract

REVIEW ARTICLE Update on Antiplatelet Therapy for Stroke Prevention Ralph L. Sacco, MD; Mitchell S. Elkind, MD he high rates of mortality and long-term disability associated with ischemic stroke, coupled with its prevalence, necessitate good, long-term preventive strategies. Risk-factor man- agement is effective for individuals with preclinical and clinical cerebrovascular dis- T ease. Patients suffering from a transient ischemic attack or stroke are particularly vul- nerable to subsequent stroke. Most of these individuals are candidates for antiplatelet treatment to prevent a recurrence. Available antiplatelet therapies include aspirin, ticlopidine, and clopidogrel. The combination of low-dose aspirin plus extended-release dipyridamole has been shown to offer safe, effective antiplatelet therapy for appropriate patients. In the second European Stroke Preven- tion Study, the combination was found to be significantly more effective than either drug alone, at the cost of relatively few treatment-related adverse effects. This combination is currently rec- ommended as one of the first-line treatments for stroke prevention after first transient ischemic attack or stroke. Stroke has a tremendous impact on pub- stroke. Until recently, the appropriate dose lic health. It is the third leading cause of of aspirin and the value of added dipyri- death and the leading cause of substan-

Journal

JAMA Internal MedicineAmerican Medical Association

Published: Jun 12, 2000

There are no references for this article.